ADAR Recombinant Protein
Produktgrößen
1mg
£1822,00
OPCA00351-1MG
Über dieses Produkt
- SKU:
- OPCA00351
- Zusätzliche Namen:
- 136 kDa double-stranded RNA-binding protein;ADAR1;adenosine deaminase acting on RNA 1-A;AGS6;double-stranded RNA-specific adenosine deaminase;DRADA;DSH;DSRAD;dsRNA adenosine deaminase;dsRNA adeonosine deaminase;G1P1;IFI4;IFI-4;interferon-induced protein 4;interferon-inducible protein 4;K88DSRBP;P136.
- Weitere Details:
- Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084; PubMed:7565688; PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP); neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site; but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV); vesicular stomatitis virus (VSV); measles virus (MV); hepatitis delta virus (HDV); and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV; MV; VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV); editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV; VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W; thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However; high levels of ADAR1 inhibit HDV replication.
- Gendetails:
- adenosine deaminase RNA specific
- Molekulargewicht:
- 35.6 kDa
- Proteindetails:
- Double-stranded RNA-specific adenosine deaminase
- Reinheit:
- Greater than 90% as determined by SDS-PAGE.
- Versandbedingungen:
- Blue Ice
- Quelle:
- E.coli
- Lagerbedingungen:
- -20Â[o]C or -80Â[o]C
- Hersteller:
- Aviva Systems Biology
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
- Datenblatt des Herstellers:html_datasheet.php